HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Stranded Biotech Asset Intelligence

Explore Opportunities

Find → Filter → Understand → Compare → Watch → Resolve. Discovery priority is not acquisition readiness.

1067 matching exact-name labels; not unique global drugs.

Select 2–10 for a subscription comparison.

UNKNOWN · LOW discovery confidence

Intravenous fluids

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravenous fluids in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Intravenous lidocaine

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravenous lidocaine in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Intravenous Nicotine

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1 Source 2 Source 3
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravenous Nicotine in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Intravenous ribavirin

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: clinical hold. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravenous ribavirin in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Intravesical Bcg

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravesical Bcg in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Intravitreal Bevacizumab

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: recruitment/execution failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravitreal Bevacizumab in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Intravitreal injection

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: recruitment/execution failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravitreal injection in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Intravitreal injection of Bevacizumab

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence, recruitment/execution failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1 Source 2
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Intravitreal injection of Bevacizumab in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

intravitreal injection of ranibizumab

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for intravitreal injection of ranibizumab in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

intravitreal injection of triamcinolone

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for intravitreal injection of triamcinolone in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

iNTS-GMMA Dose A

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for iNTS-GMMA Dose A in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

iNTS-GMMA Dose B

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for iNTS-GMMA Dose B in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →